Table 4.
Summary of pharmacokinetic measurements and percentage attaining target at various simulated doses. Cmax = peak serum concentration. AUC0–24 = serum total area under the concentration time curve. IQR= interquartile range.
| Drug | Simulated Dose (mg) | Target | Cmax (mg/L) | AUC0–24 (mg·h/L) | ||
|---|---|---|---|---|---|---|
| Median (IQR) | Attaining Target (%) | Median (IQR) | Attaining Target (%) | |||
| Rifampin | 600 | Cmax: 8 mg/L | 4.6 (3.4–6.4) | 16.30 | 34.5 (26.3–42.2) | 43.6 |
| 900 | 6.8 (4.8–9.6) | 34.7 | 52.3 (36.6–63.5) | 78 | ||
| 1200 | 9 (6.3–12.7) | 57.1 | 71.2 (48.1–84) | 92.7 | ||
| 1500 | AUC0–24: 35.4 mg·h/L | 11.2 (7.9–16) | 73.5 | 90.6 (66.7–105.6) | 97.7 | |
| 1800 | 13.3 (9.5–19.2) | 81.6 | 108.8 (79–123.9) | 100 | ||
| Isoniazid | 300 | Cmax: 3 mg/L | 0.9 (0.7–1) | 0 | 10.2 (8.7–11.8) | 0 |
| 450 | 1.3 (1.1–1.5) | 0 | 15.3 (13.1–17.7) | 0 | ||
| 600 | 1.7 (1.5–2) | 4.1 | 20.5 (17.4–23.6) | 2.3 | ||
| 750 | AUC0–24: 52 mg·h/L | 2.2 (1.8–2.5) | 8.2 | 25.6 (21.7–29-6) | 2.3 | |
| 900 | 2.6 (2.2–3.1) | 28.6 | 30.7 (26.1–35.5) | 4.5 | ||
| Pyrazinamide | 1000 | Cmax: 20 mg/L | 25.7 (19.1–36) | 69.4 | 303.8 (231.6–466.1) | 42.9 |
| 1500 | 38 (28.7–54.3) | 89.8 | 466 (351.1–702.1) | 71.4 | ||
| 2000 | 50.4 (38.1–72.6) | 91.8 | 624.7 (469.5–934.8) | 85.1 | ||
| 2500 | AUC0–24: 363 mg·h/L | 63.1 (47.4–90.8) | 96 | 778.5 (588–1167.8) | 89.6 | |
| 3000 | 75.8 (56.7–109.2) | 98 | 933 (706.6–1403.9) | 91.7 | ||
| Ethambutol | 800 | Cmax: 2 mg/L | 1.6 (1.2–2.2) | 32.6 | 13 (10–18.6) | |
| 1200 | 2.4 (1.7–3.3) | 63.2 | 19.5 (15–28) | |||
| 1600 | 3.2 (2.3–4.4) | 89.8 | 26 (20–37.1) | |||
| 2000 | 3.9 (2.9–5.5) | 93.8 | 32.5 (25–46.4) | |||
| 2400 | 4.7 (3.5–6.5) | 93.8 | 39 (30–55.7) | |||